At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 108 enrolled
Drug / intervention
BI 671800 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled, Efficacy and Safety Cross-over Study of 4 Weeks of Oral BI 671800 ED 200 mg Twice Daily or 400 mg Once Daily Administered in the Morning (AM) or Evening (PM), in Symptomatic Asthma Patients on Inhaled Fluticasone Propionate MDI
In Brief
A Phase 2 clinical trial evaluating BI 671800 and Placebo for Asthma. Completed, enrolled 108 participants across 14 sites.
Detailed Summary
To investigate the effectiveness and safety of BI 671800 given in the morning (AM), evening (PM) or twice daily (b.i.d.) compared too placebo as add on therapy to inhaled corticosteroid in symptomatic asthma patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedMar 2010
Primary CompletionFeb 2011
Study CompletionFeb 2011
TodayJul 2026
First PostedMar 19, 2010
Enrollment StartMar 1, 2010
Primary CompletionFeb 1, 2011
Study CompletionFeb 18, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.3 years ago
Interventions
BI 671800drug
BI 671800
Placebodrug
Placebo matching BI 671800